Our product

DANYELZA (naxitamab-gqgk) 40mg/10ml Injection
Please click for full Prescribing Information and Patient Information for DANYELZA® including BOXED WARNING on serious infusion-related reactions and neurotoxicity.
Learn more about DANYELZA®
Y-mAbs Connect

Y-mAbs Connect answers questions related to access, insurance and financial support programs for eligible patients.

Y-mAbs Connect

Medical information requests

To request medical information, please call 1-833-33YMABS (1-833-339-6227) and select option 1, or you may submit a medical question to [email protected]. You may also find information on our medical website, ymabsmedical.com. The information provided on this medical website is intended only for use by healthcare professionals practicing in the United States.

Product complaints and adverse events

To report an adverse reaction or product complaint, please contact us at 1-833-33YMABS (1-833-339-6227). Reports can also be made directly to FDA at www.fda.gov/medwatch or 1-800-FDA-1088 (1-800-332-1088).

Reporting compliance concerns

To report a compliance concern, please click here, or call 844-951-1999. The Y-mAbs Compliance Integrity Hotline is a telephone and web-based confidential reporting system.

To learn more about our science, partnership opportunities, resources, careers or other inquiries, we encourage you to connect with us.

Contact us
Scroll to Top

INTENDED FOR US AUDIENCES ONLY

I understand
DANYELZA (naxitamab-gqgk) 40mg/10ml Injection

Please click for full Prescribing Information and Patient Information for DANYELZA including BOXED WARNING on serious infusion-related reactions and neurotoxicity.

Learn more at danyelza.com

INDICATION
DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partiaI response, minor response, or stable disease to prior therapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

SELECTED IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFUSION-RELATED REACTIONS and NEUROTOXICITY

Serious Infusion-Related Reactions

  • DANYELZA can cause serious infusion reactions, including cardiac arrest, anaphylaxis, hypotension, bronchospasm, and stridor. Infusion reactions of any Grade occurred in 94-100% of patients. Severe infusion reactions occurred in 32-68% and serious infusion reactions occurred in 4-18% of patients in DANYELZA clinical studies.
  • Premedicate prior to each DANYELZA infusion as recommended and monitor patients for at least 2 hours following completion of each infusion. Reduce the rate, interrupt infusion, or permanently discontinue DANYELZA based on severity.

Neurotoxicity

  • DANYELZA can cause severe neurotoxicity, including severe neuropathic pain,transverse myelitis and reversible posterior leukoencephalopathy syndrome (RPLS). Pain of any Grade occurred in 94-100% of patients in DANYELZA clinical studies.
  • Premedicate to treat neuropathic pain as recommended. Permanently discontinue DANYELZA based on the adverse reaction and severity.